1 Min Read
March 20 (Reuters) - Trillium Therapeutics Inc:
* TRILLIUM THERAPEUTICS’ TTI-621 RECEIVES ORPHAN DRUG DESIGNATION FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.